1. Sung, H.A.-O., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. (1542-4863 (Electronic)).
2. Poon, R.T., et al., Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. (0003-4932 (Print)).
3. Cheung, T.T., et al., Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. (2219-2840 (Electronic)).
4. Lai, E., et al., Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? (1879-0461 (Electronic)).
5. Chen, W., et al., Cancer statistics in China, 2015. (1542-4863 (Electronic)).
6. Maida, M., et al., Staging systems of hepatocellular carcinoma: a review of the literature. (2219-2840 (Electronic)).
7. Shi, J., et al., A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. (0007-0920 (Print)).
8. Johannesen, C.D.L., et al., Association between low-density lipoprotein and all-cause and cause specific mortality in Denmark: prospective cohort study. (1756-1833 (Electronic)).
9. Stevanovic, M., et al., Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development. (1330-0962 (Print)).
10. Agrawal, S., R.K. Dhiman, and J.K. Limdi, Evaluation of abnormal liver function tests. (1469-0756 (Electronic)).
11. Azab, B., et al., The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer. (1432-1262 (Electronic)).
12. Chen, J., et al., Low pretreatment serum globulin may predict favorable prognosis for gastric cancer patients. (1423-0380 (Electronic)).
13. Heimbach, J.K., et al., AASLD guidelines for the treatment of hepatocellular carcinoma. (1527-3350 (Electronic)).
14. Zhang, W., et al., High preoperative serum globulin in hepatocellular carcinoma is a risk factor for poor survival. (1837-9664 (Print)).
15. Ni, X.C., et al., Role of Lipids and Apolipoproteins in Predicting the Prognosis of Hepatocellular Carcinoma After Resection. (1178-6930 (Print)).
16. Gelfand, E.W., Intravenous immune globulin in autoimmune and inflammatory diseases. (1533-4406 (Electronic)).
17. Singh, R.A.-O., M.K. Mishra, and H. Aggarwal, Inflammation, Immunity, and Cancer. (1466-1861 (Electronic)).
18. Elinav, E., et al., Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. (1474-1768 (Electronic)).
19. Balkwill, F. and A. Mantovani, Inflammation and cancer: back to Virchow? (0140-6736 (Print)).
20. Vawda S Fau - Mansour, R., et al., Associations between inflammatory and immune response genes and adverse respiratory outcomes following exposure to outdoor air pollution: a HuGE systematic review. (1476-6256 (Electronic)).
21. Huang, R., et al., Sex hormone-binding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations. (1932-6203 (Electronic)).
22. Kristal, A.R., et al., Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. (1476-6256 (Electronic)).
23. Li, Q., et al., High preoperative serum globulin in rectal cancer treated with neoadjunctive chemoradiation therapy is a risk factor for poor outcome. (2156-6976 (Print)).
24. Qu, X., et al., High percentage of α1-globulin in serum protein is associated with unfavorable prognosis in non-small cell lung cancer. (1559-131X (Electronic)).
25. Wen, J., et al., The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage I-III Breast Cancer Patients Undergoing Surgical Treatment. (1932-6203 (Electronic)).
26. Pope, E.D., 3rd, et al., Aberrant lipid metabolism as a therapeutic target in liver cancer. (1744-7631 (Electronic)).
27. Yang, X., et al., Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. (1479-6821 (Electronic)).
28. Zhao, J., et al., Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: a cross-sectional study. (1475-2891 (Electronic)).
29. Lyu, Z., et al., Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. (1097-0215 (Electronic)).
30. Llanos, A.A., et al., Cholesterol, lipoproteins, and breast cancer risk in African American women. (1049-510X (Print)).
31. Fiorenza, A.M., D. Branchi A Fau - Sommariva, and D. Sommariva, Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. (0940-5437 (Print)).
32. Silbernagel, G., et al., LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. (1879-1484 (Electronic)).
33. Niu, C.Z., et al., The -250G/A and -514C/T Polymorphisms in Hepatic Lipase Gene Promoter Confers an Increased Risk of Hepatocellular Carcinoma in a Chinese Population. (1665-2681 (Print)).
34. Zhang, W., et al., Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma. (1942-5546 (Electronic)).